CY1112372T1 - Χιμαιρικα και εξανθρωπισμενα μονοκλωνικα αντισωματα εναντι ιντερλευκινης-13 - Google Patents
Χιμαιρικα και εξανθρωπισμενα μονοκλωνικα αντισωματα εναντι ιντερλευκινης-13Info
- Publication number
- CY1112372T1 CY1112372T1 CY20121100172T CY121100172T CY1112372T1 CY 1112372 T1 CY1112372 T1 CY 1112372T1 CY 20121100172 T CY20121100172 T CY 20121100172T CY 121100172 T CY121100172 T CY 121100172T CY 1112372 T1 CY1112372 T1 CY 1112372T1
- Authority
- CY
- Cyprus
- Prior art keywords
- interlekkin
- cleaned
- chemical
- antibodies against
- antibodies
- Prior art date
Links
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000019207 human interleukin-13 Human genes 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0414799.7A GB0414799D0 (en) | 2004-07-01 | 2004-07-01 | Immunoglobulins |
| GB0423675A GB0423675D0 (en) | 2004-10-25 | 2004-10-25 | Immunoglobulins |
| EP05757024A EP1802658B1 (en) | 2004-07-01 | 2005-06-30 | Chimeric and humanised monoclonal antibodies against interleukin-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112372T1 true CY1112372T1 (el) | 2015-12-09 |
Family
ID=35521159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100172T CY1112372T1 (el) | 2004-07-01 | 2012-02-21 | Χιμαιρικα και εξανθρωπισμενα μονοκλωνικα αντισωματα εναντι ιντερλευκινης-13 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7807788B2 (enExample) |
| EP (2) | EP2436697B1 (enExample) |
| JP (1) | JP5102616B2 (enExample) |
| KR (1) | KR20070034609A (enExample) |
| AR (1) | AR049565A1 (enExample) |
| AT (1) | ATE535545T1 (enExample) |
| AU (1) | AU2005259025B2 (enExample) |
| BR (1) | BRPI0512826A (enExample) |
| CA (1) | CA2571799A1 (enExample) |
| CY (1) | CY1112372T1 (enExample) |
| DK (1) | DK1802658T3 (enExample) |
| ES (2) | ES2456897T3 (enExample) |
| HR (1) | HRP20120139T1 (enExample) |
| IL (1) | IL180152A0 (enExample) |
| MA (1) | MA28726B1 (enExample) |
| MX (1) | MX2007000026A (enExample) |
| NO (1) | NO20070189L (enExample) |
| NZ (1) | NZ552063A (enExample) |
| PE (1) | PE20060376A1 (enExample) |
| PL (1) | PL1802658T3 (enExample) |
| PT (1) | PT1802658E (enExample) |
| RU (1) | RU2404192C2 (enExample) |
| SG (1) | SG153878A1 (enExample) |
| SI (1) | SI1802658T1 (enExample) |
| TW (1) | TWI307630B (enExample) |
| WO (1) | WO2006003407A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101073590B1 (ko) * | 2003-07-15 | 2011-10-14 | 메디뮨 리미티드 | Ｉｌ-13에 대한 인간 항체 분자 |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| PL1711528T3 (pl) * | 2003-12-23 | 2012-11-30 | Genentech Inc | Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| MX2007005866A (es) | 2004-11-17 | 2007-11-12 | Amgen Inc | Anticuerpos monoclonales totalmente humanos para il-13. |
| ES2412005T3 (es) | 2005-04-15 | 2013-07-09 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Tratamiento y prevención de la enfermedad intestinal inflamatoria que implica IL-13 y células NKT |
| JP2009510046A (ja) | 2005-09-30 | 2009-03-12 | メドイミューン・リミテッド | インターロイキン−１３抗体組成物 |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| AU2007209202A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
| MY161894A (en) | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008054606A2 (en) * | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| DE102008053503B4 (de) * | 2008-10-28 | 2011-04-28 | Justus-Liebig-Universität Giessen | Immunologischer Test zum Nachweis von Autoantikörpern gegen testikuläre Antigene |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| EA201190275A1 (ru) * | 2009-05-28 | 2012-11-30 | Глаксо Груп Лимитед | Белок, связывающий интерлейкин-13 (il-13) |
| PL3037104T3 (pl) | 2009-10-20 | 2020-11-16 | Abbvie Inc. | Izolacja i oczyszczanie przeciwciał anty-il-13 z zastosowaniem chromatografii powinowactwa z białkiem a |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| CN105722532A (zh) | 2013-09-13 | 2016-06-29 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
| AR098155A1 (es) | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
| AU2015214103A1 (en) | 2014-02-07 | 2016-07-21 | Abbott Laboratories | Novel assay to detect human periostin |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| CN106536754B (zh) | 2014-04-11 | 2021-04-16 | 诺华股份有限公司 | 用il-13拮抗剂选择性治疗哮喘的方法 |
| EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CN107430117A (zh) | 2015-03-16 | 2017-12-01 | 豪夫迈·罗氏有限公司 | 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途 |
| ITUB20155097A1 (it) * | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| WO2017198148A1 (zh) * | 2016-05-18 | 2017-11-23 | 上海开拓者生物医药有限公司 | 一种il-13抗体及其制备方法和应用 |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| MA46269B1 (fr) | 2017-08-18 | 2024-05-31 | Regeneron Pharma | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
| HUE064655T2 (hu) | 2017-10-30 | 2024-04-28 | Sanofi Biotechnology | IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban |
| PE20211304A1 (es) | 2018-02-09 | 2021-07-20 | Genentech Inc | Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos |
| CN112153982A (zh) | 2018-05-13 | 2020-12-29 | 瑞泽恩制药公司 | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CA3120578A1 (en) * | 2018-12-03 | 2020-06-11 | Dermata Therapeutics, Llc | Compositions for the treatment of conditions |
| CA3129963A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| MX2021011141A (es) | 2019-03-21 | 2022-01-19 | Regeneron Pharma | Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia. |
| MX2022000649A (es) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r. |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN118355034A (zh) | 2021-12-30 | 2024-07-16 | 瑞泽恩制药公司 | 施用il-4/il-13拮抗剂以减弱特应性进程的方法 |
| EP4227321A1 (en) * | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US6051231A (en) * | 1988-09-01 | 2000-04-18 | Bayer Corporation | Antiviral methods and prepations |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| BR9206313A (pt) | 1991-07-25 | 1995-04-11 | Idec Pharma Corp | Anticorpos recombinantes para terapia humana. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP0957087B1 (en) | 1994-06-15 | 2002-12-04 | The Wellcome Foundation Limited | Intermediates useful in the preparation of enzyme inhibitors |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| CA2323771A1 (en) | 1998-03-14 | 1999-09-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6468528B1 (en) * | 1999-02-01 | 2002-10-22 | Amgen Canada Inc. | Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth |
| EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| CA2423251A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
| AU2002337496A1 (en) * | 2001-09-20 | 2003-04-28 | Pioneer Corporation | Drive circuit for light emitting elements |
| CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| WO2003080675A2 (en) * | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| DE60318188T2 (de) | 2002-03-26 | 2008-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| CA2480777A1 (en) * | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| EP1575502B1 (en) | 2002-07-18 | 2010-01-20 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| CN101745112A (zh) * | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| WO2004018429A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US20060089375A1 (en) | 2002-09-16 | 2006-04-27 | Allen David G | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| CA2499150A1 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US7790405B2 (en) * | 2004-04-26 | 2010-09-07 | Centocor, Inc. | Solution phase biopanning method using engineered decoy proteins |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
-
2005
- 2005-06-29 TW TW094121993A patent/TWI307630B/zh not_active IP Right Cessation
- 2005-06-30 HR HR20120139T patent/HRP20120139T1/hr unknown
- 2005-06-30 RU RU2007103826/10A patent/RU2404192C2/ru not_active IP Right Cessation
- 2005-06-30 JP JP2007518695A patent/JP5102616B2/ja not_active Expired - Fee Related
- 2005-06-30 PL PL05757024T patent/PL1802658T3/pl unknown
- 2005-06-30 AT AT05757024T patent/ATE535545T1/de active
- 2005-06-30 CA CA002571799A patent/CA2571799A1/en not_active Abandoned
- 2005-06-30 SG SG200904563-4A patent/SG153878A1/en unknown
- 2005-06-30 PE PE2005000762A patent/PE20060376A1/es not_active Application Discontinuation
- 2005-06-30 NZ NZ552063A patent/NZ552063A/en not_active IP Right Cessation
- 2005-06-30 EP EP11181891.0A patent/EP2436697B1/en not_active Revoked
- 2005-06-30 ES ES11181891.0T patent/ES2456897T3/es not_active Expired - Lifetime
- 2005-06-30 SI SI200531473T patent/SI1802658T1/sl unknown
- 2005-06-30 EP EP05757024A patent/EP1802658B1/en not_active Expired - Lifetime
- 2005-06-30 BR BRPI0512826-9A patent/BRPI0512826A/pt not_active IP Right Cessation
- 2005-06-30 US US11/570,736 patent/US7807788B2/en not_active Expired - Fee Related
- 2005-06-30 MX MX2007000026A patent/MX2007000026A/es active IP Right Grant
- 2005-06-30 PT PT05757024T patent/PT1802658E/pt unknown
- 2005-06-30 DK DK05757024.4T patent/DK1802658T3/da active
- 2005-06-30 ES ES05757024T patent/ES2378173T3/es not_active Expired - Lifetime
- 2005-06-30 AU AU2005259025A patent/AU2005259025B2/en not_active Ceased
- 2005-06-30 KR KR1020077002166A patent/KR20070034609A/ko not_active Abandoned
- 2005-06-30 WO PCT/GB2005/002581 patent/WO2006003407A2/en not_active Ceased
- 2005-06-30 AR ARP050102731A patent/AR049565A1/es unknown
-
2006
- 2006-12-18 IL IL180152A patent/IL180152A0/en unknown
- 2006-12-29 MA MA29577A patent/MA28726B1/fr unknown
-
2007
- 2007-01-11 NO NO20070189A patent/NO20070189L/no not_active Application Discontinuation
-
2010
- 2010-08-24 US US12/862,235 patent/US20110243928A1/en not_active Abandoned
-
2012
- 2012-02-21 CY CY20121100172T patent/CY1112372T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112372T1 (el) | Χιμαιρικα και εξανθρωπισμενα μονοκλωνικα αντισωματα εναντι ιντερλευκινης-13 | |
| TW200736274A (en) | Immunoglobulins | |
| CY1120874T1 (el) | Συνθεση αντισωματος ιντερλευκινης-13 | |
| CY1120887T1 (el) | Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους | |
| NO20052591L (no) | Pyridopyrolizin og pyridoindolizinderivater | |
| ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung | |
| JO2576B1 (en) | Antibodies | |
| CY1114919T1 (el) | Anti-mag ανθρωποποιημενα αντισωματα και οι χρησεις τους για την αντιμετωπιση του εγκεφαλικου επεισοδιου | |
| DE60215000D1 (de) | DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN | |
| CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| CY1112507T1 (el) | Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β | |
| EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
| DE69634079D1 (de) | Antagoniste des vasculären endothelzellewachstumfaktors | |
| EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
| PH12013501287A1 (en) | Novel use of il-1beta compounds | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| CY1109238T1 (el) | Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη | |
| WO2009015063A8 (en) | Methods and compositions for treating fibrosis related disorders using il-17 antagonists | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| MY149492A (en) | Immunoglobulins directed against nogo | |
| FI20060188A7 (fi) | Modifioidut IL-4-muteiinin reseptorin antagonistit | |
| RU2015147913A (ru) | Антитело против рецептора эпидермального фактора роста | |
| ATE473239T1 (de) | Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren | |
| EA200702634A1 (ru) | Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения | |
| DE60321954D1 (de) | Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol |